The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma.
Yuan-Kai Shi
No relevant relationships to disclose
Mei Dong
No relevant relationships to disclose
Xiao-Nan Hong
No relevant relationships to disclose
Wei-Jing Zhang
No relevant relationships to disclose
Ji-Feng Feng
No relevant relationships to disclose
Jun Zhu
No relevant relationships to disclose
Li Yu
No relevant relationships to disclose
Xiao-Yan Ke
No relevant relationships to disclose
Hui-Qiang Huang
No relevant relationships to disclose
Zhi-Xiang Shen
No relevant relationships to disclose
Yun Fan
No relevant relationships to disclose
Wei Li
No relevant relationships to disclose
Xie-Lan Zhao
No relevant relationships to disclose
Lu-Gui Qiu
No relevant relationships to disclose
He Huang
No relevant relationships to disclose